The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

| More on:
Bored man sitting at his desk with his laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price fell to a 52-week low last week, dropping to $261.38 after the company reported its FY25 half-year result.

Created with Highcharts 11.4.3Cochlear PriceZoom1M3M6MYTD1Y5Y10YALL15 Feb 202415 Feb 2025Zoom ▾Mar '24May '24Jul '24Sep '24Nov '24Jan '25Apr '24Apr '24Jul '24Jul '24Oct '24Oct '24Jan '25Jan '25www.fool.com.au

The ASX healthcare company's half-year result clearly didn't impress the market, as it declined 14% on the day. Ouch.

The business didn't exactly report a terrible set of numbers. The company's HY25 revenue rose by 5% to $1.17 billion, underlying net profit increased 7% to $205.5 million, and statutory net profit increased 7% to $205.1 million. This allowed an 8% hike of the interim dividend per share to $2.15.

However, a number of unfavourable results were reported by the ASX healthcare share.

Negatives from Cochlear's HY25 result

After providing the main numbers the company then made a number of disappointing comments.

The company said it expects its underlying net profit to be between $410 million and $430 million, at the lower end of the guidance range provided in August 2024.

Services growth has slowed since launching the Nucleus 8 sound processor in FY23. It had expected modest service growth in FY25, but it now expects a single-digit decline.

In addition, the company's gross profit margin is expected to be around 74.5%, half a percentage point below its longer-term target of 75% due to lower overhead recoveries at the new facility in Chengdu.

Cochlear also noted that it has been investing in an operating model redesign and core business system upgrades over the past four years to improve efficiency and agility. It expects to invest around $250 million overall, an increase of $100 million from its previous estimate.

Is the Cochlear share price a buy?

After seeing the result, the broker UBS suggested the result was less bad than it looked.

The broker noted that the Cochlear implant unit growth was 6% year over year with stable pricing. The company continues to expect growth of around 10% for FY25, implying an uplift in the second half. It also sees this as a "sustainable forward run rate".

While near-term profit is not expected to be as good, the broker increased its net profit forecasts in the mid-single digits in the long term based on the Cochlear implant sales forecasts.

This helped improve the price target on the Cochlear share price to A$285. A price target is what the broker sees the share price being in 12 months.

However, UBS noted that Cochlear "still faces the prospect of a vaccine against CMV, a major cause of neonatal deafness, developed by Moderna. There is no phase III trial data yet, but it's a risk for the second half. UBS estimates at least 30% of Cochlear's implants in the US are for children at the moment.

Commenting further on the risk of a vaccine, UBS said:

…the case for this to be problematic for Cochlear is weaker than it was because a) the best case scenario efficacy-wise has not materialised for Moderna – the trial could still work but was not stopped early at an interim look and b) the appointment of a new HHS secretary in the US who is notable for his past stance on vaccines. Our prior mid single digit impact to mid term forecasts is tempered in our new forecasts. We still think there is room for downside surprise but a scenario where Moderna's trial fails or efficacy is weak would imply valuation +c.AUD10 all else equal.

UBS currently forecasts that in FY25, Cochlear could generate $2.43 billion of revenue and $415 million of net profit.

It is predicted to make $3 billion in revenue and $549 million in net profit by FY29.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Macquarie's top 3 ASX stock picks in the healthcare sector

Top broker has revealed 3 healthcare stocks with upside. 

Read more »